ImmunoPrecise subsidiary expands B cell Select platform

By The Science Advisory Board staff writers

September 22, 2020 -- IPA Europe, a subsidiary of ImmunoPrecise Antibodies, has expanded its foundational B cell Select platform for seamless integration into ImmunoPrecise's optimization and antibody developability profiling workflow.

With substantial investments, IPA Europe developed a second-generation platform that enables multispecies, target-interaction-based single B cell selection technology and subsequent single cell cloning for accelerated identification of comprehensive panels of diverse lead therapeutic antibodies.

The B cell Select platform enables interrogation of isolated B cells to analyze full organism antibody repertoires. The species independent platform can develop a range of antibodies, including any protein class, complex therapeutic target, post-translation modifications, and small molecules. The system generates monoclonal antibodies for B cell selection to accelerate the rate of the antibody discovery process.

ImmunoPrecise, Zymeworks partner on SARS-CoV-2 antibody
ImmunoPrecise and Zymeworks announced that they have formed a research collaboration to develop a multispecific SARS-CoV-2 antibody.
Immunoprecise highlights combo neutralization of antibodies
Immunoprecise Antibodies has conducted additional characterization of a subset of fully human, therapeutic SARS-CoV-2 antibodies that are potent and exhibit...
ImmunoPrecise identifies SARS-CoV-2 neutralizing antibodies
ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further...
ImmunoPrecise, NIH, Integrated Biotherapeutics test antibodies for COVID-19
ImmunoPrecise Antibodies announced that it is collaborating with the National Institute of Diabetes and Digestive and Kidney Diseases at the National...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter